NASDAQ: FHTX - Foghorn Therapeutics Inc.

Rentabilität für sechs Monate: -61.98%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Foghorn Therapeutics Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

weitere details
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2020-10-23
ISIN US3441741077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://foghorntx.com
Цена ао 3.81
Preisänderung pro Tag: -8.76% (3.88)
Preisänderung pro Woche: -12.59% (4.05)
Preisänderung pro Monat: -29.34% (5.01)
Preisänderung über 3 Monate: -26.56% (4.82)
Preisänderung über sechs Monate: -61.98% (9.31)
Preisänderung pro Jahr: -47.24% (6.71)
Preisänderung über 3 Jahre: -77.15% (15.49)
Preisänderung seit Jahresbeginn: -25% (4.72)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 8.16 1
P/BV -3.61 0
P/E 0 0
EV/EBITDA -2.45 0
Gesamt: 3.88

Effizienz

Name Bedeutung Grad
ROA, % -34.42 0
ROE, % 127.51 10
Gesamt: 3.33

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.4542 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 7843.02 10
Rentabilität Ebitda, % 109.33 10
Rentabilität EPS, % 0.2094 1
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Flagship Pioneering Inc. 12674120 29.78
FMR, LLC 2810009 6.6
Raymond James & Associates, Inc. 2068387 4.86
Euclidean Capital LLC 1573761 3.7
Blackrock Inc. 1305868 3.07
Vanguard Group Inc 1025113 2.41
Artal Group S.A. 720720 1.69
Point72 Asset Management, L.P. 540000 1.27
Alphabet Inc. 500901 1.18
Geode Capital Management, LLC 448350 1.05

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
Range Cancer Therapeutics ETF 2.15956 47.24 0.11955
iShares Micro-Cap ETF 0.06408 17.09 1.54048
iShares Russell 2000 Growth ETF 0.01111 38.04 0.6026
Vanguard Russell 2000 ETF 0.01 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
ProShares UltraPro Russell2000 0.00545 89.82 1.47873
ProShares Hedge Replication ETF 0.00149 5.92 1.47892
Avantis U.S. Equity ETF 0.0004 23.04 1.59151
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.2532.581.15



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Adrian H. B. Gottschalk President, CEO & Director 784.65k 1976 (49 Jahre)
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer 572.6k 1965 (60 Jahre)
Mr. Michael J. LaCascia Chief Legal Officer 565.5k 1965 (60 Jahre)
Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board N/A
Mr. Saurabh Sewak Ph.D. Vice President of Corporate Development N/A
Mr. Carlos Costa Chief People Officer N/A 1973 (52 Jahr)
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer 300.16k 1971 (54 Jahr)
Ms. Karin Hellsvik VP of Corporate Affairs & Investor Relations N/A
Mr. Kristian Humer M.B.A. Chief Financial Officer N/A 1976 (49 Jahre)
Dr. Anna Rivkin Ph.D. Chief Business Officer

Adresse: United States, Cambridge. MA, 500 Technology Square - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://foghorntx.com